ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Revance Therapeutics Inc

Revance Therapeutics Inc (RVNC)

3.57
0.00
(0.00%)
Closed April 25 4:00PM
0.00
0.00
(0.00%)

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.57
Bid
3.55
Ask
3.71
Volume
-
0.00 Day's Range 0.00
3.5391 52 Week Range 37.98
Market Cap
Previous Close
3.57
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,820,224
Shares Outstanding
88,214,054
Dividend Yield
-
PE Ratio
-0.97
Earnings Per Share (EPS)
-3.67
Revenue
234.04M
Net Profit
-323.99M

About Revance Therapeutics Inc

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD pl... Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Revance Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RVNC. The last closing price for Revance Therapeutics was $3.57. Over the last year, Revance Therapeutics shares have traded in a share price range of $ 3.5391 to $ 37.98.

Revance Therapeutics currently has 88,214,054 shares outstanding. The market capitalization of Revance Therapeutics is $314.92 million. Revance Therapeutics has a price to earnings ratio (PE ratio) of -0.97.

RVNC Latest News

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one...

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (“RSUs”) to 29 employees. The RSUs vest over four...

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.18-4.83.753.873.539117686683.68263146CS
4-1.43-28.655.033.539115931214.1335267CS
12-1.54-30.13698630145.117.563.539118202245.33227106CS
26-4.97-58.19672131158.549.7453.539117246366.28033266CS
52-27.69-88.579654510631.2637.983.5391168187613.23010366CS
156-25.78-87.836456558829.3537.983.5391121530518.45455835CS
260-9.54-72.768878718513.1137.983.539194759519.08236318CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.3999
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.2684
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.78
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5001
(0.00%)
0
AACGATA Creativity Global
$ 0.87
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.3999
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.2684
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.78
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5001
(0.00%)
0
AACGATA Creativity Global
$ 0.87
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.3999
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 60.2684
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.78
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.5001
(0.00%)
0
AACGATA Creativity Global
$ 0.87
(0.00%)
0

RVNC Discussion

View Posts
vinmantoo vinmantoo 16 hours ago
Consumers remember in the moment what is right in front of them and this is cringeworthy.

Consumers remember what works for them or what they hear works for their friends and associates.
👍️ 1 💯 4
stocksrising stocksrising 16 hours ago
Sad, but true to all :(
Wonder what Erica’s budget is for 2024?

Enhanced and streamlined organizational structure:
— With the appointment of Erica Jordan as Chief Commercial Officer in the fourth quarter of 2023, the commercial organization was restructured to integrate and “streamline marketing, sales, commercial operations, professional part-nerships, strategy, data analytics and professional engagement functions”. The new structure is designed to support the company's strategic priorities by enhancing execution and performance while improving efficiencies.

Tried to ascertain 23’ Marketing/Advertising budget
( 10k), but as you know S,G & A* doesn’t get broken out by segment( doesn’t matter anyway, different model this year) last year: $297,732
($223,934–2022)

*SG&A expenses include most expenses related to running a business outside of
COGS. This includes salaries, rent, utilities, “advertising, marketing”, technology, and supplies not used in manufacturing.

Well, only couple weeks before Q1, so strap in , LFG !!! RVNC
👍️0
vinmantoo vinmantoo 16 hours ago
Allergan has a great strategy here. They’ve got deep enough pockets to hire million dollar influencers (Kris Jenner promoting Botox gift cards) and they keep it more grassroots with casting calls. Revance is using C tier influencers because of budget constraints and the scripting/performance at that level can feel contrived.

Sounds like Allergan is scared and panicking. A superior product like Daxxify doesn't need to try and sway people with big advertising spending.

Ms.Dtox, for someone whose financial well-being is so tied up in RVNC you sure love to dis RVNC every chance you get. I don't think I ever read you say anything positive about RVNC or about Daxxify. Let's put aside your continuing attacks on RVNC management for a second. Do you at least think Daxxify is superior to Botox?
👍️ 4
Emannow Emannow 16 hours ago
Allergan has always used and uses external marketing agencies for all of their ads and marketing materials! Botox has a product manager and assistant product manager…2 people. The assistant is the fill in for the product manager when they move to another job!

Allergan is most likely seeing a slow erosion of Botox sales and they are using influencers to try and slow the erosion! Remember, it cost $5 full load cost to produce a vial of Botox and AbbVie sells it for $656 per vial. Botox is the cash cow of aesthetics so AbbVie wants that profit at ALL costs!
👍️ 3
Ms.Dtox Ms.Dtox 16 hours ago
It’s kind of embarrassing that a year ago Daxxify was presented as an elite allocated product to create FOMO demand and now Daxxify is being pitched by a minor mom influencer, it’s like we don’t even know who or what we are. Vogue and Time Magazine and the pendulum swing to this? Consumers remember in the moment what is right in front of them and this is cringeworthy. 😕
👍️ 1 😂 1 🤡 1
Ms.Dtox Ms.Dtox 17 hours ago
Allergan has a great strategy here. They’ve got deep enough pockets to hire million dollar influencers (Kris Jenner promoting Botox gift cards) and they keep it more grassroots with casting calls. Revance is using C tier influencers because of budget constraints and the scripting/performance at that level can feel contrived. There is no marketing team left, so everything we see in near future will be outside agency generated with the agency fee taking the biggest bite out of marketing budget. There is no effective strategy in place at this time.
👍️ 2 😂 1
stocksrising stocksrising 19 hours ago
Marketing heating up in this space! Revance can’t let guard down, should be an interesting 2nd half, 2024

https://www.fiercepharma.com/marketing/abbvie-starts-open-casting-call-next-faces-botox-ads-doubling-down-pitch-everyday-users
👍️0
go seek go seek 19 hours ago
I agree… perhaps so we remember it. 🙃
👍️0
marthambles marthambles 19 hours ago
I think that ad is pretty annoying actually.
👍️ 2
go seek go seek 1 day ago
New DAXXIFY ad… ‘different’
https://www.instagram.com/reel/C6HC2SlO3xX/?igsh=c3I2YWN2dmlqeDEx
👍️ 1 😬 1
Emannow Emannow 1 day ago
Oracle is moving its headquarters to Nashville. Hopefully, Foley will rent out the 18th floor with 2 bars and change his title to Commercial Real Estate Broker! This is a perfect time for Foley to resign as the RVNC CEO and move to a job which matches his skill set! Commercial Relator. 🥳🥳🥳
🤣 2
alertmeipp alertmeipp 2 days ago
Daxxify is simply a better product in the market. Now with proper marketing strategy, sales should improve steadily.

The upside for here is just enormous even assuming very conservative market share

Don’t understand the continuous selling at all.
👍️ 1
soma2022 soma2022 2 days ago
Daxxify dysphagia rates reported at 2.7 to 4.2%:

https://www.biospace.com/article/releases/u-s-fda-approves-first-therapeutic-indication-for-revance-s-daxxify-daxibotulinumtoxina-lanm-for-injection-for-the-treatment-of-cervical-dystonia/

Based on the ASPEN OLS study, symptoms continued to improve with successive DAXXIFY® treatments at doses up to 300U, while adverse events remained low.15-16 In particular, dysphagia rates (difficulty swallowing) remained low (2.7% for ASPEN-1 and 4.2% for ASPEN-OLS), further supporting DAXXIFY’s safety profile.15-16

Botox at 19%

https://www.botoxone.com/cervical-dystonia#:~:text=The%20most%20frequently%20reported%20adverse,%2C%20and%20headache%20(11%25).

The most frequently reported adverse reactions following injection of BOTOX for cervical dystonia include dysphagia (19%), upper respiratory infection (12%), neck pain (11%), and headache (11%).

I would expect that dysphagia rates with botox have dropped over time as technique has improved.

Revance also detailed Dysphagia rates in their presentation at the shareholder meeting last September and I believe that presentation is available on the Investor relation page of their website.
👍️ 11
mrwilson31 mrwilson31 2 days ago
I can’t find the page where it shows a side by side comparison. That’s what you stated.
👍️0
mrwilson31 mrwilson31 2 days ago
Still have not answered my question about your background.
👍️ 1
Emannow Emannow 2 days ago
Please review the clinical trials!

Why would Daxi have lower adverse events and Daxi injectors are being instructed to inject Daxi directly into the intended muscle! Daxi attaches very quickly to the neuron and does not spread! Versus Botox injection technique for the glabellar area which on the top side of the muscle knowing Botox will spread and cause adverse events.

Compare the 2 injection patterns published! Daxi just published their updated pattern versus the Botox pattern!

Now you know why Botox must be higher and why it takes up to 14 days to get the full effect! The Botox active ingredient floats around for several days and some finds the neurons..half of the active ingredient attaches to other tissues!
👍️ 1
mrwilson31 mrwilson31 2 days ago
Is that your expert opinion as to why there is more adverse events or is that from clinical experience?

👍️ 1
Emannow Emannow 2 days ago
Yes, there is no head to head comparison published! One must compare the data from both PI’s.

Allergan will never tell patients that their active toxin floats around for up to 2 weeks in the patient’s tissues! Easy to understand why Daxi with the same active ingredient as Botox gives the patient double the duration of Botox. The Botox active ingredient attaches to many other areas and half never finds the neurons! The Botox active ingredient attached to areas not intended! That is why Botox has higher adverse events than Daxi in every clinical application!

The peptide in Daxi is the magic!
👍️ 1
mrwilson31 mrwilson31 2 days ago
I did. I don’t see the head to head comparison. I understand the peptide portion of Daxi.

So are you just making a claim or a comparison?

It’s not as easy as you think.

👍️0
Emannow Emannow 2 days ago
Please review the PI for both Botox and Daxi for CD and compare!
👍️0
Emannow Emannow 2 days ago
There are many unhappy RVNC employees who have lost money with the SP. The SP will correct itself as RVNC sales grow and expenses are managed which will show profits! Foley is a hatchet man and reworked the RVNC business model with the new price of Daxi!

Daxi will be released early in May for CD. There are already orders for CD so shipments will happen immediately!

Cosmetic Daxi sales will continue to grow as the sales team works hard to teach accounts how to inject Daxi, make more profit and give patients an improved toxin experience.
👍️ 3
mrwilson31 mrwilson31 2 days ago
Where does it state that in the PI?

Which section? Can you point me to that part of the clinical study?

Would love to read that. I’m kind of nerdy like that.
👍️0
Emannow Emannow 2 days ago
Please review the adverse events for Botox vs Daxi for CD! The Botox activate ingredient floates around in the tissue for up to 2 weeks and some attaches to the neuron..some goes elsewhere! The peptide in Daxi is attracted to the neuron and begins to attach immediately..nothing floating around after 5 days.

This is why injectors of Botox tell their patients to keep their head up and no exercise immediately after. They know Botox floats everywhere and that is why Botox has higher adverse events than Daxi!

That simple!
👍️ 1
AXRX4952 AXRX4952 2 days ago
@Emannow - I find that where there is smoke there is fire on these posts....worth reading what's being said on the inside pharma co chat boards. Most people don't know this exists but it does. https://www.cafepharma.com/boards/forums/revance-biotech.1254/
👍️ 1 💩 2
mrwilson31 mrwilson31 2 days ago
You are completely making a false claim about adverse events.
👍️0
go seek go seek 2 days ago
Interesting… Todays extended hours volume nearly the same as the daily volume.
👍️0
alertmeipp alertmeipp 2 days ago
I thought he meant advertising events
😂 2 🙄 1
go seek go seek 2 days ago
This is why Botox has so many adverse events!… I did not know that Botox causes more adverse events per se.
👍️0
Emannow Emannow 3 days ago
Spoke to a Derm office who was a 100% Botox office for 15 yrs. They are now charging $7.75 per unit for Daxi and $14 per unit for Botox. Their patients love Daxi and are willing to pay an additional $60 per treatment ( 80 units of Daxi vs 40 units of Botox) to receive the quick onset, double the duration of Botox and improve peptide skin tone! The Daxi patient onset is 3 days versus Botox at 12 days. Do patients really want that Botox Toxin floating around in their tissue for 2 weeks? This is why Botox has so many adverse events!

The injector makes an extra $500 to $750 profit per day injecting Daxi vs Botox.

This is a win for both patients and injectors. Of course, more injectors will continue to switch to Daxi. Injectors make more profit per hour!!!
👍️ 6 🤑 1
go seek go seek 3 days ago
Lots of new clinics advertising…
Yes, I agree…that is my experience also.
👍️ 2
edcoolidge edcoolidge 3 days ago
Lots of new clinics advertising the addition of Daxxify every week. Allergan and Galderma's kickback crony CosmeticMDs can deceive their clients for only so long.

👍️ 2
vinmantoo vinmantoo 3 days ago
This drawdown might yet turn out to be a blessing for the believers.

Actually, I haven't drawn down my position overall. I buy back after the wash period passes. So far I have been able to buy back at lower price so have more shares each time. We will have to see whether or not that was a foolish move.
🍀 1 👍️ 2
alertmeipp alertmeipp 3 days ago
This drawdown might yet turn out to be a blessing for the believers. We will see in couple years.
👍️ 2 💩 2
vinmantoo vinmantoo 3 days ago
either way, shorts have been right along from close to 40pps to now below 4

Can't hide from that fact. 😩

The only "positive" on my end is most of my earlier buys were in the teens and I have been able to generate some losses to offset capital gains.
👍️ 2
alertmeipp alertmeipp 3 days ago
One thing for sure, if the fundamental is there, this stock will bounce one day and we will go up many folds in a year

Worst case is this gets sold at basement price and Foley hands over all upside to buyers
👍️ 2
alertmeipp alertmeipp 3 days ago
Ian is either pretty smart if he is pretending to be dumb to tick people off or he is actually naive

Can’t tell

But either way, shorts have been right along from close to 40pps to now below 4
👍️ 3
vinmantoo vinmantoo 3 days ago
Does your post contain any facts?

If so, provide some links.

What?? I stated a series of facts. Do you want a link showing that there was a total eclipse of the sun over much of the US recently?

The first is that the Fed isn’t continuing to tighten. It stopped some time ago and is waiting for the right time to cut rates.

Do you actually want a link to that? It has been in all the news. Okay, here.

https://tradingeconomics.com/united-states/interest-rate

https://www.nytimes.com/2024/03/20/business/fed-meeting-interest-rates.html

Second, inflation is under control as it was reading just above the Fed’s 2% target.

Do you want a link to that? It has been in all the news.


As far as inflation, it was supply chain bottlenecks as we came out of the pandemic combined with disruptions in the energy markets and in geopolitical stability due to Russia’s war on Ukraine that drove the inflation spikes. Corporate greed now is driving a portion of inflation now.

Do you want a link showing that supply chain issues were the driver of inflation?? Oh give me a freaking break. Don't you read the news?

Do you want a link showing that Russia's invasion of Ukraine roiled the energy markets and generated geopolitical instabilities? Oh give me a freaking break. Don't you read the news?

Do you want a link showing that corporate greed is during inflation? It has been in all the news.

https://www.theguardian.com/business/2024/jan/19/us-inflation-caused-by-corporate-profits?utm_term=65aa7257ea2501ec1a892c80b1b2e848&utm_campaign=GuardianTodayUS&utm_source=esp&utm_medium=Email&CMP=GTUS_email
👍️ 1
IanFromSI IanFromSI 3 days ago
Does your post contain any facts?

If so, provide some links.
👍️ 1 💩 3 🤡 1
vinmantoo vinmantoo 3 days ago
Interesting post but it contains key factual errors. The first is that the Fed isn’t continuing to tighten. It stopped some time ago and is waiting for the right time to cut rates. Second, inflation is under control as it was reading just above the Fed’s 2% target. As far as inflation, it was supply chain bottlenecks as we came out of the pandemic combined with disruptions in the energy markets and in geopolitical stability due to Russia’s war on Ukraine that drove the inflation spikes. Corporate greed now is driving a portion of inflation now.


As far as ENTA, you didn’t follow it but feel you need to comment on its current low state. Many people including myself profited from it’s HepC drugs and some of us invested some of that money back as ENTA price dropped, one of them is myself.
👍️ 2
go seek go seek 4 days ago
Of course Revance Therapeutics will survive. Highly respected dermatologists tout DAXXIFY as A Best in Class Product and the first true innovation in the space in 30 years. Management has adjusted its marketing strategy. Engage with customers through competitive pricing and enhanced messaging that highlights DAXXIFY’s unique peptide formulation, long duration, fast onset and improved skin quality appearance. New patients love the product. Daxi sales should exceed expectations going forward. RHA Collections sales are solid, more excellent products with high growth potential. ADD in potential partnerships and marketing opportunities outside the US.
👍️ 3
IanFromSI IanFromSI 4 days ago
Milton Friedman (Nobel prize winner for economics) famously said: “Inflation is always and everywhere a monetary phenomenon, in the sense that it is and can be produced only by a more rapid increase in the quantity of money than in output.”

For more than a decade, the fed gave money away for free or close to it and flooded the market with decade of quantitative easing or excess liquidity. . Those days are now over.

The fed is aggressively tightening and will continue to do so until inflation is definitely under control. This is definitely not the utopia emerging biotechs have become accustomed to.

Roy’s Blindspot appears to be managerial competence. MNTA lost its IP for two potential blockbusters in a row before investors were rescued by JNJ. I never followed.Enanta, I don’t know whether that was a managerial mistake or simply having a pipeline which became obsolete prior to enough approvals. … or something else.

The RVNC perma bulls Seem to be utterly disgusted with Foley. Not a good indicator for any company.

If the company is not profitable in a year, it may never be able to get there. …. And Roy’s track record in picking fabulous management is far from stellar.

Is it can take more than 10% of the toxin market within a year, it will probably survive.
👍️ 2 💩 1 😂 1 🤡 1
PioneerUniverse8 PioneerUniverse8 4 days ago
Ian you seem like a smart guy, but you are too pessimistic about RVNC's prospects. With the pricing adjustment they have a fair shot at making a lot of money. I will reply to this post in about a year and admit that I was wrong, or that you were just unreasonably pessimistic.
👍️ 3
IanFromSI IanFromSI 5 days ago
Two more milestones are approaching, once reached, even more institutional investors will no longer be allowed to own RVNC.
💩 2 🤡 1 🤥 1
go seek go seek 5 days ago
High % Shorts… probably related to the weak market and options trading. I think the short trade will soon reverse on this one. Bottom probably was put in at $3.7., but I’m no expert. Hopefully we get some positive feedback from management in the near future.
👍️0
Emannow Emannow 5 days ago
Yesterday, the shorts were 61% of the trades and Thursday, 51%, Wednesday 60%…

Any thoughts on why the shorts would be working so hard to depress the SP?
👍️0
go seek go seek 5 days ago
💋 Are u ready for your close-up?
https://www.instagram.com/reel/C59Scu-JBSJ/?igsh=aDN1NW0zbWJhNGR1
👍️0
go seek go seek 5 days ago
$249… no crows feet!
https://www.instagram.com/reel/C5qpTlaAKQn/?igsh=OW9saXNhdmRiMDNl
👍️ 1
DewDiligence DewDiligence 6 days ago
Nothing has changed regarding double-dose Jeuveau since the post I'm replying to; it remains a gimmick that has little consequence in the marketplace.

Reply to 'iwfal' on Biotech Values board:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174265867
👍️ 6
go seek go seek 6 days ago
(Audio) How many customers stay w Daxxi?

https://www.instagram.com/reel/C2i6DfSO1Kd/?igsh=MWUzOXhxejgxb3hvaA==

Revive Clinic
👍️ 2
edcoolidge edcoolidge 7 days ago
Clearly the EOLS data was meant to convince unsophisticated CosmetcMDs and not investors.
👍️ 1 🤡 1

Your Recent History

Delayed Upgrade Clock